On September 2008, PharmEste closed the second financing stage (Round B) for a total of € 6 Million, to be mainly used for the pre-clinical and clinical development of the PHE377 compound. The investment is supported by two of the financial partners of the first round financing , namely Z-Cube s.r.l. ,the corporate venture of the Zambon Company S.p.A , and Quantica SGR(Italian leading vc Company), the Asset Management Company dedicated to innovative Venture capital activities and by two new financial partners: Emilia Venture, managed by MPS Venture SGR (Montepaschi Group) and MP Healthcare Venture Management Inc., the Boston Venture fund jointly owned by Mitsubishi Tanabe Pharma Corporation and Mitsubishi Chemical Holdings Corporation in Japan.
On January 2007 PharmEste closed a €3.2 million Round A financing with Z-Cube srl as lead investor and Quantica SGR, Zernike Meta Ventures, Fondamenta Sgr as co-investors.